Why is Pacific Edge (ASX:PEB) raising NZ$24 million in new capital?

Pacific Edge is raising funds to strengthen its balance sheet and provide the "runway" needed to regain US Medicare coverage for its Cxbladder tests. The company currently faces a liquidity squeeze following a 2025 decision that halted Medicare reimbursements, which significantly impacted its cash flow.

What happened to Pacific Edge (ASX:PEB) revenue in FY26?

Unaudited preliminary results for FY26 show that operating revenue dropped sharply to $11.5 million, down from $21.8 million in FY25. This nearly 50% revenue decline was caused by the loss of US Medicare coverage, which led to a 21.4% drop in US laboratory throughput.

Is Pacific Edge (ASX:PEB) currently profitable?

No, Pacific Edge is not profitable and its losses are currently widening. For FY26, the company reported a net loss of $35.7 million, an increase from the $29.9 million loss recorded in FY25.

How has Pacific Edge (ASX:PEB) managed its cash burn and expenses?

The company has aggressively cut costs, trimming total expenses to $49.3 million and reducing its monthly cash burn by 27.7% in the second half of FY26. As of March 2026, cash reserves had tightened to $7.8 million, down from $22.6 million a year prior.

What are the main risks for investors buying Pacific Edge (ASX:PEB) shares now?

The primary risk is "regulatory binary risk"—the company’s future is heavily dependent on a single decision by the Medicare contractor, Novitas. If Novitas issues a negative Local Coverage Determination (LCD), Pacific Edge may struggle to regain its primary revenue source in the US.

Does Pacific Edge (ASX:PEB) have any growth outside of the US market?

Yes, the APAC region remains a bright spot, with test volumes increasing by 7.9% in FY26. While the US remains the company's largest potential market and its primary "growth engine," the resilience in the APAC region provides some geographical diversification.

What is the next major catalyst to watch for Pacific Edge (ASX:PEB) shareholders?

Investors should closely watch for a draft Local Coverage Determination (LCD) from Novitas regarding hematuria evaluation. This regulatory update will determine if Cxbladder Triage (and potentially Triage Plus) will regain Medicare coverage.

Image for illustrative purposes only. Not a real photo.

Pacific Edge launches NZ$24M raise amid losses

Q: How is the Pacific Edge (ASX:PEB) capital raising structured for retail and institutional investors?

The capital raise is split into two components: an NZ$18 million placement dedicated to institutional investors and a NZ$6 million offer specifically for retail participants. All new shares are priced at NZ$0.170 per share.

Written by Mahathir BayenaPublished May 10, 2026, 10:44 PM

Cancer diagnostics firm Pacific Edge (ASX:PEB) has launched a capital raise to secure up to NZ$24 million, priced at NZ$0.170 per share.

The initiative includes an NZ$18 million placement to institutional investors and a NZ$6 million offer for retail participants.

The liquidity injection is critical as the company navigates a challenging fiscal landscape, aimed at regaining vital US Medicare coverage for its Cxbladder tests—a cornerstone for the firm’s long-term commercial scalability.

Pacific Edge released unaudited preliminary financial results for the 2026 fiscal year, revealing the stark impact of the 2025 Medicare non-coverage determination.

Operating revenue plummeted to $11.5 million, a drop from the $21.8 million reported in FY25.

The downturn was driven by a 21.4% decline in total US laboratory throughput, as the company faced the dual hurdles of selling non-covered products and transitioning customers between test variants.

The APAC region showed resilience, with volumes increasing by 7.9%.

Total expenses were trimmed to $49.3 million, and monthly cash burn was successfully reduced by 27.7% in the second half of the year.

However, the net loss widened to $35.7 million, and cash reserves tightened to $7.8 million by March.

The company remains focused on a pending local coverage determination from Novitas, which could potentially reinstate Medicare reimbursement and stabilise its primary growth engine.